S&P 500   4,212.84 (+0.79%)
DOW   33,091.43 (+0.56%)
QQQ   350.00 (+0.58%)
AAPL   179.33 (+1.17%)
MSFT   329.60 (+0.37%)
META   268.76 (+1.53%)
GOOGL   122.93 (+0.05%)
AMZN   121.84 (+1.04%)
TSLA   203.70 (-0.11%)
NVDA   392.61 (+3.77%)
NIO   7.56 (+0.40%)
BABA   82.97 (+4.30%)
AMD   119.37 (+0.98%)
T   15.86 (+0.83%)
F   12.10 (+0.83%)
MU   68.95 (+1.10%)
CGC   0.85 (+2.35%)
GE   104.35 (+2.78%)
DIS   88.37 (+0.47%)
AMC   4.63 (+2.89%)
PFE   38.13 (+0.29%)
PYPL   62.91 (+1.48%)
NFLX   400.79 (+1.41%)
S&P 500   4,212.84 (+0.79%)
DOW   33,091.43 (+0.56%)
QQQ   350.00 (+0.58%)
AAPL   179.33 (+1.17%)
MSFT   329.60 (+0.37%)
META   268.76 (+1.53%)
GOOGL   122.93 (+0.05%)
AMZN   121.84 (+1.04%)
TSLA   203.70 (-0.11%)
NVDA   392.61 (+3.77%)
NIO   7.56 (+0.40%)
BABA   82.97 (+4.30%)
AMD   119.37 (+0.98%)
T   15.86 (+0.83%)
F   12.10 (+0.83%)
MU   68.95 (+1.10%)
CGC   0.85 (+2.35%)
GE   104.35 (+2.78%)
DIS   88.37 (+0.47%)
AMC   4.63 (+2.89%)
PFE   38.13 (+0.29%)
PYPL   62.91 (+1.48%)
NFLX   400.79 (+1.41%)
S&P 500   4,212.84 (+0.79%)
DOW   33,091.43 (+0.56%)
QQQ   350.00 (+0.58%)
AAPL   179.33 (+1.17%)
MSFT   329.60 (+0.37%)
META   268.76 (+1.53%)
GOOGL   122.93 (+0.05%)
AMZN   121.84 (+1.04%)
TSLA   203.70 (-0.11%)
NVDA   392.61 (+3.77%)
NIO   7.56 (+0.40%)
BABA   82.97 (+4.30%)
AMD   119.37 (+0.98%)
T   15.86 (+0.83%)
F   12.10 (+0.83%)
MU   68.95 (+1.10%)
CGC   0.85 (+2.35%)
GE   104.35 (+2.78%)
DIS   88.37 (+0.47%)
AMC   4.63 (+2.89%)
PFE   38.13 (+0.29%)
PYPL   62.91 (+1.48%)
NFLX   400.79 (+1.41%)
S&P 500   4,212.84 (+0.79%)
DOW   33,091.43 (+0.56%)
QQQ   350.00 (+0.58%)
AAPL   179.33 (+1.17%)
MSFT   329.60 (+0.37%)
META   268.76 (+1.53%)
GOOGL   122.93 (+0.05%)
AMZN   121.84 (+1.04%)
TSLA   203.70 (-0.11%)
NVDA   392.61 (+3.77%)
NIO   7.56 (+0.40%)
BABA   82.97 (+4.30%)
AMD   119.37 (+0.98%)
T   15.86 (+0.83%)
F   12.10 (+0.83%)
MU   68.95 (+1.10%)
CGC   0.85 (+2.35%)
GE   104.35 (+2.78%)
DIS   88.37 (+0.47%)
AMC   4.63 (+2.89%)
PFE   38.13 (+0.29%)
PYPL   62.91 (+1.48%)
NFLX   400.79 (+1.41%)
NASDAQ:KMDA

Kamada (KMDA) Stock Forecast, Price & News

$4.76
-0.07 (-1.45%)
(As of 11:39 AM ET)
Compare
Today's Range
$4.75
$4.83
50-Day Range
$4.36
$5.40
52-Week Range
$3.72
$5.72
Volume
13,758 shs
Average Volume
35,769 shs
Market Capitalization
$213.34 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$11.00

Kamada MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
127.7% Upside
$11.00 Price Target
Short Interest
Healthy
0.01% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.34mentions of Kamada in the last 14 days
Based on 16 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
100.00%
From $0.09 to $0.18 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.65 out of 5 stars

Medical Sector

94th out of 1,006 stocks

Pharmaceutical Preparations Industry

33rd out of 492 stocks


KMDA stock logo

About Kamada (NASDAQ:KMDA) Stock

Kamada Ltd. is a biopharmaceutical company, which focuses on specialty plasma-derived therapeutic. It operates through the Proprietary Products and Distribution segments. The Proprietary Products segment covers the development, manufacture, and sale of plasma-derived protein therapeutics products. The Distribution segment covers the drug products in Israel, which are manufactured by third parties. The company was founded by David Tsur and Ralf Hahn on December 13, 1990 and is headquartered in Rehovot, Israel.

Receive KMDA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Kamada and its competitors with MarketBeat's FREE daily newsletter.

KMDA Stock News Headlines

AI Getting Close to Thinking Like Humans
Technology experts working with neuroscientists have created the world's first Artificial Intelligence Network Operating System. AI can now process information like the human brain and understand the world the way humans do.
StockNews.com Initiates Coverage on Kamada (NASDAQ:KMDA)
Graphite Shortage Could Derail the $7 Trillion EV Transition
Graphite (not lithium) is expected to see the largest increase in demand of all battery metals over the next decade. But projections warn of an 8 million ton shortfall of graphite by 2040. That's why 97 more graphite mines are needed just to keep up with battery production for the $7 trillion transition to electric vehicles.
Kamada: Q1 Earnings Insights
Kamada: Q1 Earnings Snapshot
Here's what Wall Street expects from Kamada's earnings
Kamada Q1 2023 Earnings Preview
Kamada Earnings Preview
See More Headlines

KMDA Price History

KMDA Company Calendar

Last Earnings
3/15/2023
Today
6/01/2023
Next Earnings (Estimated)
8/16/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:KMDA
Employees
355
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$11.00
High Stock Price Forecast
$11.00
Low Stock Price Forecast
$11.00
Forecasted Upside/Downside
+127.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-2,320,000.00
Pretax Margin
-1.72%

Debt

Sales & Book Value

Annual Sales
$129.34 million
Cash Flow
$0.02 per share
Book Value
$3.90 per share

Miscellaneous

Free Float
28,640,000
Market Cap
$216.48 million
Optionable
Not Optionable
Beta
0.99

Key Executives

  • Amir London
    Chief Executive Officer
  • Eran Nir
    Chief Operating Officer
  • Naveh Tov
    VP-Clinical Development & Medical Director
  • Nir Livneh
    Secretary, Vice President & General Counsel
  • Boris Gorelik
    VP-Business Development & Strategic Programs













KMDA Stock - Frequently Asked Questions

Should I buy or sell Kamada stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Kamada in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" KMDA shares.
View KMDA analyst ratings
or view top-rated stocks.

What is Kamada's stock price forecast for 2023?

1 equities research analysts have issued 12-month price targets for Kamada's shares. Their KMDA share price forecasts range from $11.00 to $11.00. On average, they anticipate the company's share price to reach $11.00 in the next year. This suggests a possible upside of 127.7% from the stock's current price.
View analysts price targets for KMDA
or view top-rated stocks among Wall Street analysts.

How have KMDA shares performed in 2023?

Kamada's stock was trading at $4.01 at the beginning of the year. Since then, KMDA stock has increased by 20.4% and is now trading at $4.83.
View the best growth stocks for 2023 here
.

Are investors shorting Kamada?

Kamada saw a decrease in short interest in the month of May. As of May 15th, there was short interest totaling 5,400 shares, a decrease of 60.6% from the April 30th total of 13,700 shares. Based on an average trading volume of 20,300 shares, the short-interest ratio is currently 0.3 days. Currently, 0.0% of the shares of the stock are sold short.
View Kamada's Short Interest
.

When is Kamada's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 16th 2023.
View our KMDA earnings forecast
.

How were Kamada's earnings last quarter?

Kamada Ltd. (NASDAQ:KMDA) issued its quarterly earnings data on Wednesday, March, 15th. The biotechnology company reported $0.11 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.07 by $0.04. The biotechnology company had revenue of $45.44 million for the quarter, compared to the consensus estimate of $44.64 million. Kamada had a positive trailing twelve-month return on equity of 8.15% and a negative net margin of 1.74%.

What guidance has Kamada issued on next quarter's earnings?

Kamada updated its FY 2023 earnings guidance on Friday, May, 26th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $138.00 million-$146.00 million, compared to the consensus revenue estimate of $141.36 million.

What other stocks do shareholders of Kamada own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Kamada investors own include CA (CA), BlackRock (BLK), Endologix (ELGX), Chipotle Mexican Grill (CMG), Athabasca Oil (ATH), Allergan (AGN), NIC (EGOV), Micron Technology (MU), Teva Pharmaceutical Industries (TEVA) and Aegean Marine Petroleum Network (ANW).

What is Kamada's stock symbol?

Kamada trades on the NASDAQ under the ticker symbol "KMDA."

Who are Kamada's major shareholders?

Kamada's stock is owned by many different institutional and retail investors. Top institutional shareholders include Renaissance Technologies LLC (1.89%), Acadian Asset Management LLC (1.44%), Altshuler Shaham Ltd (0.79%), Meitav Investment House Ltd. (0.15%) and UBS Group AG (0.11%).

How do I buy shares of Kamada?

Shares of KMDA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Kamada's stock price today?

One share of KMDA stock can currently be purchased for approximately $4.83.

How much money does Kamada make?

Kamada (NASDAQ:KMDA) has a market capitalization of $216.48 million and generates $129.34 million in revenue each year. The biotechnology company earns $-2,320,000.00 in net income (profit) each year or ($0.05) on an earnings per share basis.

How many employees does Kamada have?

The company employs 355 workers across the globe.

How can I contact Kamada?

Kamada's mailing address is 2 HOLTZMAN ST. SCIENCE PARK, REHOVOT L3, 7670402. The official website for the company is www.kamada.com. The biotechnology company can be reached via phone at (728) 940-6472, via email at ir@kamada.com, or via fax at 972-8940-6473.

This page (NASDAQ:KMDA) was last updated on 6/1/2023 by MarketBeat.com Staff

My Account -